CoChat

Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study

Open access
Rajasekeran, Harindra, Reich, Heather N., Hladunewich, Michelle A., Cattran, Daniel, Lovshin, Julie A., Lytvyn, Yuliya, Bjornstad, Petter, Lai, Vesta, Tse, Josephine, Cham, Leslie, Majumder, Syamantak, Bowskill, Bridgit B., Kabir, M. Golam, Advani, Suzanne L., Gibson, Ian W., Sood, Manish M., Advani, Andrew, Cherney, David Z. I. · 2018 · American Journal of Physiology-Renal Physiology
Cited by 87

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy attenuates the progression of diabetic nephropathy, but it remains unclear whether SGLT2i provides renoprotection in nondiabetic CKD such as FSGS. The primary aim of this pilot study was to determine the effect of 8 wk of dapagliflozin on glomerular filtration rate (GFR) in humans and in experimental FSGS. Secondary end points were related to changes in renal hemodynamic function, proteinuria, and blood pressure (BP). GFR (inulin) and renal plasma flow (para-aminohippurate), proteinuria, and BP were measured in patients with FSGS ( n = 10), and similar parameters were measured in subtotally nephrectomized (SNx) rats. In response to dapagliflozin, changes in GFR, renal plasma flow, and 24-h urine protein excretion were not statistically significant in humans or rats. Systolic BP (SBP) decreased in SNx rats (196 ± 26 vs. 165 ± 33 mmHg; P < 0.001), whereas changes were not statistically significant in humans (SBP 112.7 ± 8.5 to 112.8 ± 11.2 mmHg, diastolic BP 71.8 ± 6.5 to 69.6 ± 8.4 mmHg; P = not significant), although hematocrit increased (0.40 ± 0.05 to 0.42 ± 0.05%; P = 0.03). In archival kidney tissue from a separate patient cohort, renal parenchymal SGLT2 mRNA expression was decreased in individuals with FSGS compared with controls. Short-term treatment with the SGLT2i dapagliflozin did not modify renal hemodynamic function or attenuate proteinuria in humans or in experimental FSGS. This may be related to downregulation of renal SGLT2 expression. Studies examining the impact of SGLT2i on markers of kidney disease in patients with other causes of nondiabetic CKD are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajprenal.00445.2017

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 87

Metadata

Authors
Rajasekeran, H., Reich, H. N., Hladunewich, M. A., Cattran, D., Lovshin, J. A., Lytvyn, Y., Bjornstad, P., Lai, V., Tse, J., Cham, L., Majumder, S., Bowskill, B. B., Kabir, M. G., Advani, S. L., Gibson, I. W., Sood, M. M., Advani, A., & Cherney, D. Z. I.
Venue
American Journal of Physiology-Renal Physiology
Published
2018-03-01
Volume
314
Issue
3
Pages
F412-F422
ISSN
  • 1522-1466 (ISSN-L)
  • 1931-857X
OpenAlex
W2769932926
Cited by
87
References
5
FWCI
6.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. https://app.cochat.ai/papers/10.1152/ajprenal.00445.2017
The paper
Rajasekeran, H., Reich, H. N., Hladunewich, M. A., Cattran, D., Lovshin, J. A., Lytvyn, Y., Bjornstad, P., Lai, V., Tse, J., Cham, L., Majumder, S., Bowskill, B. B., Kabir, M. G., Advani, S. L., Gibson, I. W., Sood, M. M., Advani, A., & Cherney, D. Z. I. (2018). Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. American Journal of Physiology-Renal Physiology. https://doi.org/10.1152/ajprenal.00445.2017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.